Germany’s drug assessment body said data provided by Bayer on the precision cancer drug Vitrakvi did not provide clear enough evidence of benefits, in a setback to the drugmaker in the company’s home market.
Although there were some deals announced at the ongoing J.P. Morgan Healthcare Conference, biotech stocks appeared to slide slightly at the overall lack of business transactions, at least during the first day or two.
Intra-Cellular Therapies Inc.’s lead drug to treat schizophrenia in adults received approval from the U.S. Food and Drug Administration, sending the company’s shares soaring 85 percent.
Cigna Corp. agreed to sell the health insurer’s disability and accidental death insurance unit for company employees to New York Life Insurance Co. in a $6.3 billion deal.
Alnylam’s gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study, bringing the company a step closer to marketing the first approved treatment for the condition.
A late-stage trial failed to show that BeiGene Ltd.’s cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc., for treating WM.
Biogen is discontinuing development of an experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest setback in attempts to develop a medicine for the disorder.
Merck & Co. Inc. is buying ArQule Inc. for $2.7 billion, seeking to tap into the drug developer’s experimental blood cancer therapy that targets genetic mutations.
Nearly half of lymphoma patients treated with Gilead Sciences Inc.’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to presented data.
The U.S. Food and Drug Administration approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis (RA) drug Remicade.
